These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 20180679)

  • 1. A small sample randomized clinical trial methodology using N-of-1 designs and mixed model analysis.
    Ridenour TA; Hall DL; Bost JE
    Am J Drug Alcohol Abuse; 2009; 35(4):260-6. PubMed ID: 20180679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the most powerful analysis method for school-based intervention studies with alcohol, tobacco, and other drug outcomes.
    Janega JB; Murray DM; Varnell SP; Blitstein JL; Birnbaum AS; Lytle LA
    Addict Behav; 2004 May; 29(3):595-606. PubMed ID: 15050677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sample size calculator for cluster randomized trials.
    Campbell MK; Thomson S; Ramsay CR; MacLennan GS; Grimshaw JM
    Comput Biol Med; 2004 Mar; 34(2):113-25. PubMed ID: 14972631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases.
    van der Lee JH; Wesseling J; Tanck MW; Offringa M
    J Clin Epidemiol; 2008 Apr; 61(4):324-30. PubMed ID: 18313556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simple sample size formula for analysis of covariance in randomized clinical trials.
    Borm GF; Fransen J; Lemmens WA
    J Clin Epidemiol; 2007 Dec; 60(12):1234-8. PubMed ID: 17998077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effectiveness of a school-based substance abuse prevention program: 18-month follow-up of the EU-Dap cluster randomized controlled trial.
    Faggiano F; Vigna-Taglianti F; Burkhart G; Bohrn K; Cuomo L; Gregori D; Panella M; Scatigna M; Siliquini R; Varona L; van der Kreeft P; Vassara M; Wiborg G; Galanti MR;
    Drug Alcohol Depend; 2010 Apr; 108(1-2):56-64. PubMed ID: 20080363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings.
    Bedard PL; Krzyzanowska MK; Pintilie M; Tannock IF
    J Clin Oncol; 2007 Aug; 25(23):3482-7. PubMed ID: 17687153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Designing a sequentially randomized study with adherence enhancing interventions for diabetes patients.
    Buyze J; Van Rompaye B; Goetghebeur E
    Stat Med; 2010 May; 29(10):1114-26. PubMed ID: 20101597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parametric versus non-parametric statistics in the analysis of randomized trials with non-normally distributed data.
    Vickers AJ
    BMC Med Res Methodol; 2005 Nov; 5():35. PubMed ID: 16269081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blinded sample size recalculation in multicentre trials with normally distributed outcome.
    Jensen K; Kieser M
    Biom J; 2010 Jun; 52(3):377-99. PubMed ID: 20394080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blinded sample size reestimation in non-inferiority trials with binary endpoints.
    Friede T; Mitchell C; Müller-Velten G
    Biom J; 2007 Dec; 49(6):903-16. PubMed ID: 17726715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Robustness and power of analysis of covariance applied to ordinal scaled data as arising in randomized controlled trials.
    Sullivan LM; D'Agostino RB
    Stat Med; 2003 Apr; 22(8):1317-34. PubMed ID: 12687657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interpreting sexually transmissible infection prevention trials by adjusting for the magnitude of exposure.
    Wilson DP
    Clin Trials; 2010 Feb; 7(1):36-43. PubMed ID: 20007407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive design and estimation in randomized clinical trials with correlated observations.
    Yin G; Shen Y
    Biometrics; 2005 Jun; 61(2):362-9. PubMed ID: 16011682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An efficient algorithm to determine the optimal two-stage randomized multinomial designs in oncology clinical trials.
    Zhang Y; Mietlowski W; Chen B; Wang Y
    J Biopharm Stat; 2011 Jan; 21(1):56-65. PubMed ID: 21191854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cluster randomized controlled trial of school-based prevention of tobacco, alcohol and drug use: the EU-Dap design and study population.
    Faggiano F; Richardson C; Bohrn K; Galanti MR;
    Prev Med; 2007 Feb; 44(2):170-3. PubMed ID: 17084887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing the validity and utility of randomized clinical trials in addictions treatment research: II. Participant samples and assessment.
    Del Boca FK; Darkes J
    Addiction; 2007 Aug; 102(8):1194-203. PubMed ID: 17511752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods.
    Willan A; Kowgier M
    Clin Trials; 2008; 5(4):289-300. PubMed ID: 18697843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A method for determining the size of internal pilot studies.
    Sandvik L; Erikssen J; Mowinckel P; Rødland EA
    Stat Med; 1996 Jul; 15(14):1587-90. PubMed ID: 8855484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing the sample size during clinical trials with t-distributed test statistics without inflating the type I error rate.
    Timmesfeld N; Schäfer H; Müller HH
    Stat Med; 2007 May; 26(12):2449-64. PubMed ID: 17080491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.